Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib.
Tripathi A, Supko JG, Gray KP, Melnick ZJ, Regan MM, Taplin ME, Choudhury AD, Pomerantz MM, Bellmunt J, Yu C, Sun Z, Srinivas S, Kantoff PW, Sweeney CJ, Harshman LC. Tripathi A, et al. Among authors: pomerantz mm. Clin Cancer Res. 2020 Dec 1;26(23):6122-6131. doi: 10.1158/1078-0432.CCR-20-2306. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943461 Free PMC article. Clinical Trial.
Advances in the treatment of prostate cancer.
Pomerantz M, Kantoff P. Pomerantz M, et al. Annu Rev Med. 2007;58:205-20. doi: 10.1146/annurev.med.58.101505.115650. Annu Rev Med. 2007. PMID: 16987081 Review.
Genetic determinants of prostate cancer risk.
Pomerantz MM, Freedman ML, Kantoff PW. Pomerantz MM, et al. BJU Int. 2007 Aug;100(2):241-3. doi: 10.1111/j.1464-410X.2007.06996.x. Epub 2007 Jun 2. BJU Int. 2007. PMID: 17542988 No abstract available.
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Ross RW, et al. Among authors: pomerantz m. Cancer. 2008 Mar 15;112(6):1247-53. doi: 10.1002/cncr.23304. Cancer. 2008. PMID: 18293426 Free article. Clinical Trial.
Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.
Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. Penney KL, et al. Clin Cancer Res. 2009 May 1;15(9):3223-30. doi: 10.1158/1078-0432.CCR-08-2733. Epub 2009 Apr 14. Clin Cancer Res. 2009. PMID: 19366828 Free PMC article.
Evaluation of the 8q24 prostate cancer risk locus and MYC expression.
Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Pomerantz MM, et al. Cancer Res. 2009 Jul 1;69(13):5568-74. doi: 10.1158/0008-5472.CAN-09-0387. Epub 2009 Jun 23. Cancer Res. 2009. PMID: 19549893 Free PMC article.
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.
Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML. Pomerantz MM, et al. Nat Genet. 2009 Aug;41(8):882-4. doi: 10.1038/ng.403. Epub 2009 Jun 28. Nat Genet. 2009. PMID: 19561607 Free PMC article.
123 results